MarketBeat
03 Oct 2026, 01:02 UTC · 2h ago
Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
Impact · against what's priced in
ACET receives a positive catalyst from strong early-stage efficacy (54% remission) and a clear FDA pathway for a pivotal study. While the cohort is small, the absence of severe toxicity and the ability to conduct outpatient enrollment differentiate prula-cel from existing CAR-T therapies.
- ACET+0.70
No priced-in read yet
- In context
The 54% DORIS remission rate and FDA alignment on a single-arm pivotal study provide a concrete valuation floor, though the 2028/2029 timeline for data means the market is now pricing in a long-duration binary event.
Read from the article alone
